FibroBiologics, Inc. (FBLG) Stock Statistics & Valuation Metrics

FibroBiologics, Inc. has a market cap or net worth of $4.56M. The enterprise value is $2.43M.

FibroBiologics, Inc. has 5,208,915 shares outstanding. The number of shares has decreased by -2.65% in one year.

FibroBiologics, Inc.’s return on equity (ROE) is -3.03 and return on invested capital (ROIC) is -194.36%.

The current PE Ratio of FibroBiologics, Inc. is ―. FibroBiologics, Inc.’s PEG ratio is -0.02.

In the last 12 months, FibroBiologics, Inc. had revenue of 0.00 and earned -18.65M in profits. Earnings per share was -8.40.

In the last 12 months, operating cash flow was -15.48M and capital expenditures -219.00K, giving a free cash flow of -15.70M billion.

FibroBiologics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

FibroBiologics, Inc. upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

FibroBiologics, Inc. as a current ratio of 3.61, with Debt / Equity ratio of 95.31%

In the past 12 months, FibroBiologics, Inc. has paid 0.00 in taxes.

FibroBiologics, Inc. EV to EBITDA ratio is -0.43, with an EV/FCF ratio of -0.45.

FibroBiologics, Inc. has $1.48M in cash and marketable securities with $2.48M in debt, giving a net cash position of -$996.00K billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for FibroBiologics, Inc. is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy